Biocon Limited (NSE:BIOCON)
India
· Delayed Price · Currency is INR 392.65
+4.30 (1.11%)
At close: Dec 5, 2025
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2005 - 2019 |
| Biosimilars | 89.29B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biosimilars Growth | 1.26% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Research | 35.86B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Research Growth | 4.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Generics | 27.47B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Generics Growth | 9.87% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Novels | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Novels Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2005 - 2019 |
| United States | 70.42B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Growth | 9.10% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| European Union (including Ireland) | 38.48B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| European Union (including Ireland) Growth | 9.42% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of the World | 33.95B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of the World Growth | 6.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| India | 9.77B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| India Growth | -39.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Ireland | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Ireland Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|